8-K current report · filed Nov 4, 2026

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) 8-K Current Report: November 4, 2026

Item 5.02Item EX-99.1Item 2.02PACB overview

Short answer

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results announced for quarter ended September 30, 2026.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 fiscal 2026 results announced for quarter ended September 30, 2026
  • Exhibit 99.1 contains the financial results and management commentary
  • Results announcement gives investors updated performance information for Pacific Biosciences’ sequencing business

Item 5.02 · Departure/Election of Directors or Officers

  • CFO Jim Gibson stepped down November 3, 2026, creating executive finance-transition risk
  • Gibson remains an advisor through March 31, 2027, retaining salary, 2026 bonus eligibility and equity vesting
  • Proposed severance includes a $500,000 lump-sum payment plus COBRA premiums for up to 12 months
  • CEO Mark Van Oene assumes interim CFO duties while the Board searches for a permanent replacement
  • Bill Meyer becomes Chief Accounting Officer and principal accounting officer, adding continuity after serving as controller since August 2026

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $40.6M, up from $38.4M, led by instrument revenue $13.2M versus $11.3M
  • Consumables revenue fell to $20.8M from $21.3M, while annualized Revio pull-through declined to ~$204,000 from ~$236,000
  • Gross margin compressed to 33% GAAP and 36% non-GAAP, pressured by memory costs and Vega manufacturing transition costs
  • Cash and investments declined to $199.4M from $298.7M year-over-year, alongside $643.1M of convertible senior notes
  • Full-year 2026 revenue outlook set at $155M to $160M, with CFO Jim Gibson departing and Mark Van Oene serving as interim CFO

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K filings

Get the next PACB 8-K as it lands

Follow PACB for push alerts, or ask the research agent what this filing means.